Progress of double hit lymphoma and double expression lymphoma

VernacularTitle:双打击淋巴瘤与双表达淋巴瘤的研究进展
Author: Huiling GUO ¹ ; Tao WU ; Hai BAI
Author Information

1. 联勤保障部队第九四○医院血液病中心，兰州　730050
From: Journal of Leukemia & Lymphoma 2020;29(5):307-309
CountryChina
Language:Chinese
Abstract: In 2016, the World Health Organization redefined double hit lymphoma and double expression lymphoma as high-grade lymphoma, a group lymphoma characterized by aggressive disease and poor prognosis. Double hit lymphoma and double expression lymphoma are related to the abnormal expressions of c-myc, bcl-2 and bcl-6 genes. Because of the differences in disease progression and prognosis of both lymphomas, R-CHOP is less effective in treating them. The adjusted R-Hyper-CVAD, R-CODOX-M/IVAC and R-EPOCH regimens have shown good results, but targeted therapy may be the most effective regimen due to their specific genetic abnormalities. This article will review its clinical characteristics, pathogenesis, diagnosis and treatment of double hit lymphoma and double expression lymphoma.